1-4 of 4
Concepcion Nicolas, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cell Free Tumor DNA for DLBCL Genotyping in a Phase II Randomized Trial Comparing Standard RCHOP Versus Brcap As First Line Treatment in Patients with Poor IPI DLBCL

Nerea Martinez, PhD, Sonia González de Villambrosia, MD, Ainara Pereña, Raul Tonda, Sergi Beltran, PhD, Marta Gut, PhD, Estrella Carrillo-Cruz, MD, Carlos Grande, MD, Alejandro Martín, MD, Concepcion Nicolas, MD, Jose Maria Roncero, MD, Maria J. Rodriguez-Salazar, MD, Jaime Perez De Oteyza, MDPhD, Eulogio Conde, MD PhD, Eva Gonzalez-Barca, Santiago Montes-Moreno, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1676.
https://doi.org/10.1182/blood-2018-99-113757
Published: 2018
Journal Articles

Mutational Landscape, Clonal Evolution Patterns and Role of RAS Mutations in Relapsed Acute Lymphoblastic Leukemia

Koichi Oshima, MD PhD, Hossein Khiabanian, PhD, Ana Carolina da Silva Almeida, PhD, Gannie Tzoneva, PhD, Francesco Abate, PhD, Alberto Ambesi-Impiombato, MD PhD, Marta Sanchez-Martin, PhD, Zachary Carpenter, PhD, Alexander Penson, PhD, Arianne Perez-Garcia, PhD, Cornelia Eckert, PhD, Concepción Nicolás, MD, Milagros Balbin, Maria Luisa Sulis, MD, Motohiro Kato, MD PhD, Katsuyoshi Koh, MD, Maddalena Paganin, Giuseppe Basso, MD, Julie M. Gastier-Foster, PhD, Meenakshi Devidas, PhD, Mignon L. Loh, MD, Renate Kirschner-Schwabe, PhD, Teresa Palomero, PhD, Raul Rabadan, PhD, Adolfo A. Ferrando, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4068.
https://doi.org/10.1182/blood.V128.22.4068.4068
Published: 2016
Journal Articles

Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo

Eva González-Barca, MD PhD, Estrella Carrillo-Cruz, MD, Carlos Grande, MD PhD, Alejandro Martín, MD PhD, Mónica Coronado, MD, Santiago Montes-Moreno, MD, Santiago Mercadal, MD, Josep Maria Roncero, MD, Jaime Pérez de Oteyza, MD, Concepción Nicolás, MD, María José Rodríguez-Salazar, MD, Juan-Manuel Sancho, Luis Palomera, MD PhD, Javier López-Jiménez, MD, Carmen Albo, MD, Francisco-Javier Peñalver, MD, José Ángel Hernández, MD, Armando López-Guillermo, MD PhD, María José Ramírez, MD, Isidro Jarque, MD, Joan Bargay, MD, Miguel Canales, MD PhD, Eulogio Conde, MD PhD, Dolores Caballero, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4201.
https://doi.org/10.1182/blood.V128.22.4201.4201
Published: 2016
Journal Articles

Outcome and Long Term Toxicity of the LNH- PRO Trial after 12 Year Median Follow-up, in Patients with Indolent Non Hodgkin's Lymphoma Who Received Immunochemotherapy with CVP and Interferon-alfa2b (IFNα2b)

Jimena Cannata-Ortiz, MD, Concepción Nicolás, MD, Ana García-Noblejas, MD, Javier Lopez, Pilar Sabin, Pilar Zamora, Maria José Requena, Reyes Arranz, MD PhD
Journal: Blood
Blood (2014) 124 (21): 4465.
https://doi.org/10.1182/blood.V124.21.4465.4465
Published: 2014